

**61st American Society of Hematology Annual Meeting and Exposition
Orlando, Florida – December 7-10, 2019
Abstracts**

MCRN-003 / CCTG MYX.1: Overall and Progression Free Survival from the MCRN-003/MYX.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Time: Saturday, December 7, 2019: 5:30 – 7:30 PM

Location: Hall B, Level 2 (Orange County Convention Center)

Type: Poster

Session: 653 – Myeloma: Therapy, excluding Transplantation: Poster I

Presenter: Christopher P. Venner

Abstract: *Overall and Progression Free Survival from the MCRN-003/MYX.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma (#1871)*

Authors: Christopher P Venner, Richard Leblanc, Irwindeep Sandhu, Darrell J White, Andrew Belch, Donna E Reece, Christine I Chen, Sean Dolan, Marc Lalancette, Martha L Louzada, Andrea Kew, Arleigh McCurdy, Tony Reiman, Max Sherry, Gail T. McDonald, Bethany Elaine Monteith, Engin Gul, Bingshu E. Chen, Annette E. Hay.

Link: https://ashpublications.org/blood/article/134/Supplement_1/1871/427726/Overall-and-Progression-Free-Survival-from-the

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Time: Monday, December 9, 2019: 6:45 PM

Location: W414 AB, Level 4 (Orange County Convention Centre)

Type: Oral

Session: 621 – Lymphoma – Genetic/Epigenetic Biology: DLBCL Genomics and Molecular Signatures

Presenter: Christopher Rushton

Abstract: *Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP (#921)*

Authors: Christopher Rushton, Sarah E Arthur, Miguel Alcaide, Matthew Cheung, Nicole Thomas, Laura K Hilton, Neil R Michaud, Scott Daigle, Jordan Davidson, Kevin R Bushell, Stephen Yu, Michael D. Jain, Lois E. Shepherd, Michael Crump, Koren Kathleen Mann, John Kuruvilla, Sarit Assouline, Kirstie Cleary, Mark S Cragg, David W. Scott, Nathalie Johnson, Ryan D. Morin.

Link: https://ashpublications.org/blood/article/134/Supplement_1/921/427044/Recurrent-Patterns-of-Clonal-Evolution-in-Relapsed

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B-Cell Lymphoma

Time: Monday, December 9, 2019: 6:00 – 8:00 PM
Location: Hall B, Level 2 (Orange County Convention Centre)
Type: Poster
Session: 626 – Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) – Results from Prospective Clinical Trials – Poster III
Presenter: Sattva S. Neelapu
Abstract: ***A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B-Cell Lymphoma (#4095)***
Authors: Sattva S Neelapu, Frederick L. Locke, Nancy L Bartlett, Lazaros J Lekakis, Patrick M Reagan, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, Michael Crump, John Kuruvilla, Eric Van Den Neste, Umar Farooq, Lynn Navale, Venita DePuy, Jenny J. Kim, Christian Gisselbrecht
Link: https://ashpublications.org/blood/article/134/Supplement_1/4095/424289/A-Comparison-of-Two-Year-Outcomes-in-ZUMA-1

CCTG LY.12 - Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Time: Monday, December 9, 2019: 4:00 PM
Location: W230, Level 2 (Orange County Convention Centre)
Type: Oral
Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) – Results from Retrospective/Observational Studies: Cellular Therapies
Presenter: Sarit Assouline
Abstract: ***Event-Free Survival as a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral (#768)***
Authors: Sarit Assouline, Shen Li, Christian Gisselbrecht, Patrick Fogarty, Annette E. Hay, Eric Van Den Neste, Lois E. Shepherd, Norbert Schmitz, Tara Baetz, Armand Keating, Sue Robinson, Matthew D. Seftel, Caterina Stelitano, Marina S. Djurfeldt, Ralph Meyer, Bingshu E. Chen, Michael Crump
Link: https://ashpublications.org/blood/article/134/Supplement_1/768/426999/Event-Free-Survival-As-a-Surrogate-for-Overall

SWOG 1612 / CCTG ALC.5 – Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Time: Monday, December 9, 2019: 6:00 – 8:00 PM
Location: Hall B, Level 2 (Orange County Convention Centre)
Type: Poster
Session: 616 – Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Presenter: Annette E. Hay
Abstract: ***Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial (#3905)***
Authors: Annette E. Hay, Sarit Assouline, Roland B. Walter, Richard F. Little, Anna Moseley, Sperling M Gail, Annie Im, James M. Foran, Jerald P. Radich, Min Fang, Megan Othus, Harry P. Erba, Laura C. Michaelis
Link: https://ashpublications.org/blood/article/134/Supplement_1/3905/424154/Accrual-Barriers-and-Detection-of-Early-Toxicity

ECOG 1411 / CCTG LYC.1 – Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendustamine-Rituximab (BR)-Based Induction Followed by Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Time: Monday, December 9, 2019: 2:45 PM

Location: Hall D, Level 2 (Orange County Convention Centre)

Type: Oral

Session: 623 – Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma – Clinical Studies: Mantle Cell Lymphoma: Frontline and Relapsed Therapies

Presenter: Mitchell Smith

Abstract: ***Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendustamine-Rituximab (BR)-Based Induction Followed by Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL) (#751)***

Authors: Mitchell Smith, Opeyemi Jegede, Samir Parekh, Curtis A. Hanson, Peter Martin, Brian G. Till, Michael Crump, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl, Thomas E. Witzig

Link: https://ashpublications.org/blood/article/134/Supplement_1/751/427083/Minimal-Residual-Disease-MRD-Assessment-in-the
